Conditional Deletion of Jak2 Reveals an Essential Role in Hematopoiesis throughout Mouse Ontogeny: Implications for Jak2 Inhibition in Humans

JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths

(2012) A. Tefferi   BLOOD

Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis

(2012) J. Mascarenhas et al.   CLINICAL CANCER RESEARCH

Rho-kinase regulates energy balance by targeting hypothalamic leptin receptor signaling

(2012) Hu Huang et al.   NATURE NEUROSCIENCE

Challenges Facing JAK Inhibitor Therapy for Myeloproliferative Neoplasms

(2012) Ayalew Tefferi   NEW ENGLAND JOURNAL OF MEDICINE

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

(2011) S Hart et al.   LEUKEMIA

Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis

(2011) Ayalew Tefferi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Critical role of Src-Syk-PLC 2 signaling in megakaryocyte migration and thrombopoiesis

(2010) A. Mazharian et al.   BLOOD

Intrinsic and extrinsic effects of mafG deficiency on hematopoietic recovery following bone marrow transplant

(2010) Xiao-Miao Li et al.   EXPERIMENTAL HEMATOLOGY

The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure

(2010) Christophe Guilluy et al.   NATURE MEDICINE

Inhibition of JAK2 protects renal endothelial and epithelial cells from oxidative stress and cyclosporin A toxicity

(2008) Fernando Neria et al.   KIDNEY INTERNATIONAL